MMP-3 was significantly reduced by the addition of adalimumab therapy in patients with rheumatoid arthritis (23) and by TNF-α antagonist therapy (infliximab, etanercept, and adalimumab) in patients with spondyloarthritis (24,25). Here, TNF is linked to rheumatoid arthritis.